Cystic Fibrosis Patients are Pharmacokinetically Comparable to Healthy Volunteers J. Bulitta 1, S. B. Duffull 2, M. Kinzig-Schippers 1, U. Holzgrabe 3,

Slides:



Advertisements
Similar presentations
POPULATION PHARMACOKINETICS OF CEFTRIAXONE IN INTENSIVE CARE UNIT (ICU) ADULT PATIENTS C Le Guellec (1), N Simon (2), D.Garot (3), R. Respaud (1), P Lanotte.
Advertisements

Azithromycin Pharmacokinetics in Pregnancy James H. Fischer, Pharm.D., FCCP May 17, 2011.
Pharmacokinetics as a Tool
The BigWinPops and MM-USCPACK Programs, USC Laboratory of Applied Pharmacokinetics ( The BigWinPops and MM-USCPACK Programs, USC Laboratory.
Dosage Regimen Design in Patients with Renal Insufficiency Cont’d Pharmacy 732 Winter, 2001.
One-compartment open model: Intravenous bolus administration
Christoffer W Tornoe Oct Population PK Model Building 1 Q & A on Session 1 What is naïve pooled analysis? –Definition –One advantage/disadvantage.
Figure 1. Diagnostic plots for propofol pharmacokinetics and effect (BIS) in morbidly obese patients including observations versus individual- predictions.
Dose Adjustment in Renal and Hepatic Disease
INTRAVENOUS INFUSION.
Lucile Packard Children’s Hospital
Modelling and Simulation Group, School of Pharmacy Pharmacokinetic design optimization in children and estimation of maturation parameters: example of.
Report Exemplar. Step 1: Purpose State the purpose of your investigation. Pose an appropriate comparison investigative question and do not forget to include.
Analysis of Zidovudine pharmacokinetics to determine whether there is a genetic component to the variability and to determine the bioequivalence of seven.
CLEARANCE CONCEPTS Text: Applied Biopharm. & PK
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
PK/PD Modeling in Support of Drug Development Alan Hartford, Ph.D. Associate Director Scientific Staff Clinical Pharmacology Statistics Merck Research.
Valproic Acid Software and Presentation by: Ted, Rob, Jeff, Cassie, Tristan, Korin, Ron, Gabe, Matt, Judith, Lindsay.
Dosing Regimen Individualization Body Size Variability in Body Size Does one size fit all ? If body size is outside the range  25% of normal (for 70.
Determination of Sample Size: A Review of Statistical Theory
Statistical considerations Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
SALIVARY, PROTEIN UNBOUND AND TOTAL PLASMA CONC OF RIFAMPICIN HADIJA H SEMVUA 11/12/2015KCRI_PhD SYMPOSIUM
Conclusions An appreciable dose-concentration-response relationship between NN1731 and F 1+2 was expressed in a population PK/PD model. Since F 1+2 appearance.
Population PK-PD Modeling of Anti-Infective Agents
Population Pharmacokinetic Characteristics of Levosulpiride and Terbinafine in Healthy Male Korean Volunteers Yong-Bok Lee College of Pharmacy and Institute.
Model structure  Law of mass action applied to describe the reversible solifenacin-AGP, solifenacin-albumin and solifenacin-VBC binding  VBC positioned.
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Bioequivalence Dr Mohammad Issa Saleh.
Noncompartmental Models. Introduction The noncompartmental approach for data analysis does not require any specific compartmental model for the system.
1 METHODS FOR DETERMINING SIMILARITY OF EXPOSURE-RESPONSE BETWEEN PEDIATRIC AND ADULT POPULATIONS Stella G. Machado, Ph.D. Quantitative Methods and Research.
CHARACTERIZATION OF THE TIME-VARYING CLEARANCE OF RITUXIMAB IN NON-HODGKIN’S LYMPHOMA PATIENTS USING A POPULATION PHARMACOKINETIC ANALYSIS METHODS INTRODUCTION.
Examples of deficiencies in submitted data Drs. J. Welink Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October.
Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand D-optimal Adaptive Bridging Studies in Pharmacokinetics Lee-Kien Foo.
Prof. Dr. Henny Lucida, Apt
Pharmacokinetics of Vancomycin in Adult Oncology Patients Hadeel Al-Kofide MS.c; Iman Zaghloul PhD; and Lamya Al-Naim PharmD Department of Clinical Pharmacy,
Pk/Pd modelling : Clinical Implications
INTERMITTENT IV VANCOMYCIN WHAT DOSE SHOULD WE START WITH?
1.Andersson, T, et al. Clin Pharmacokinet 2001;40: Hassan-Alin, M, et al. Eur J Clin Pharmacol 2000;56: Population Pharmacokinetic Modelling.
1. Objectives Novartis is developing a new triple fixed-dose combination product. As part of the clinical pharmacology program, pharmacokinetic (PK) drug-drug.
Chapter 6: Descriptive Statistics. Learning Objectives Describe statistical measures used in descriptive statistics Compute measures of central tendency.
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.
Adequacy of beta-lactam antibiotic dosing in critically ill children on continuous renal replacement therapy: A pilot study. Diaz F 1,2, Benner KW 3, Sewell.
Stats Methods at IC Lecture 3: Regression.
Allie punke pharmcokinetics Allie punke
LIPOPHILIC AND PROTEIN BOUND ANTIBIOTICS ARE MORE LIKELY TO HAVE ALTERED PHARMACOKINETCIS DURING ECMO Kiran Shekar, Jason Roberts, Sara Diab, Adrian Barnett,
Pharmacokinetics of Vancomycin in Adult Oncology Patients
Lecture-8 Biopharmaceutics
Module 6: Descriptive Statistics
Oral session: PK/PD-based optimized broad-spectrum beta-lactam therapy (Sunday 10 April, 11:30) Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets.
Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation  Martin Roderfeld, Timo Rath, Richard Schulz, Werner Seeger,
Clinical Pharmacokinetics
Clinical Pharmacokinetics
You need: Pencil Agenda Scrap Paper AP log Math book Calculator
Multivariate Data credits AS91582.
Predictive Performance of a Myelosuppression Model for Dose Individualization; Impact of Type and Amount of Information Provided Johan E. Wallin, Lena.
NONCOMPARTMENTAL ANALYSIS
Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function  William R. Hunt, Beth R. Helfman,
IL-18; IL-18BP; and free, biologically active IL-18 levels in nonsevere versus severe dengue cases. IL-18; IL-18BP; and free, biologically active IL-18.
No, she only ordered one wheel for each triangle No, she only ordered one wheel for each triangle. She should have order 30 wheels. 3 = #of wheels.
Covariates of tramadol disposition in the first months of life
Clinical Pharmacokinetics
Q1: Drug A is a small and hydrophilic compound that distributes to extracellular fluids only. It has a volume of distribution of 5.6 L in a healthy 70-kg.
Homework: Maintenance Sheet 28 via Study Island- Answer all 30 questions in diagnostic test
Homework: Maintenance Sheet 28 via Study Island- Answer all 30 questions in diagnostic test
Figure 2 Distinct changes to immunoprofile in autoimmune thyroid disease (AITD) and multiple sclerosis (MS)‏ Distinct changes to immunoprofile in autoimmune.
Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients  Rosa F. Yeh,
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis  D.J. Touw, A.J. Knox,
A change in either volume of distribution or clearance has differing effects on the concentration-time profile. A change in either volume of distribution.
Presentation transcript:

Cystic Fibrosis Patients are Pharmacokinetically Comparable to Healthy Volunteers J. Bulitta 1, S. B. Duffull 2, M. Kinzig-Schippers 1, U. Holzgrabe 3, U. Stephan 1,4, F. Sörgel 1,4 1: IBMP, Nürnberg, Germany 2: University of Queensland, Australia 3: University of Würzburg, Germany 4: University of Duisburg – Essen, Germany

Objectives 1)To compare average clearance (CL) and volume of distribution (Vd) between cystic fibrosis (CF) patients and healthy volunteers.  “Does CF alter pharmacokinetics?” 2)To study which body size descriptor reduces the unexplained between subject variability in CL and Vd most.  “How to achieve target concentrations more precisely?”

Literature data 1 studies with CF-patients and healthy volunteers (H) Range for the Ratio of average Ratio of average clearance volume of distribution CL(CF) / CL(H)*Vd(CF) / Vd(H)** Penicillins1.17 – – 1.41 Cephalosporins0.95 – – 1.44 Aminoglycosides0.83 – – 1.42 Ciprofloxacin0.90 – – 1.62 *Clearance expressed as L/h/kg total body weight (or as L/h/m 2 BSA). **Volume of distribution expressed as L/kg total body weight (or L/m 2 ). 1 Touw DJ et al., Clin Pharmacokinet 1998, 35:

Clinical studies 10* antibiotics (7 beta-lactams, 3 quinolones) Similar clinical protocols All studies with a healthy volunteer control group Frequent plasma and urine samples Similar clinical study conditions for CF-patients and healthy volunteers Validated HPLC analysis in a single laboratory *: Carumonam, cefaclor, cefadroxil, cefotiam, ceftazidime, cefpirome, ciprofloxacin, fleroxacin, pefloxacin, piperacillin

Demographics *Cheymol & James formula

Pharmacokinetic analysis Population PK with NONMEM® V (FOCE with interaction) 2-compartment models Exponential between subject variability model Model qualification via visual predictive checks Non-parametric bootstrap for point estimates (medians) & confidence intervals (Perl / NONMEM®) Statistics and non-compartmental analysis with WinNonlin®

Size models Size modelNameExponent for CLVd 1) No size model noWT Total body weight 2)Linear scaling WT11.0*1.0 3)Allometric scaling WT0.75**1.0 Lean body mass 4) Linear scaling LBM11.0*1.0 5)Allometric scalingLBM0.75**1.0 *: “Double the size, double the clearance.” **: “Double the size, increase clearance by 68%.”

Average ratios for 10 antibiotics after size adjustment Total clearance (CL) Volume of distribution at steady-state (Vdss) CL(CF) / CL(H) Vdss(CF) / Vdss(H) Marker: Median of 10 drugs, Box: inter-quartile range, Whisker: Min-Max

Reduction of unexplained between subject variability (BSV) Renal clearance Reduction of unexplained BSV Marker: Median of 10 drugs, Box: inter-quartile range, Whisker: Min-Max  Reduction of BSV by 20-25% after adjusting for the average difference in renal clearance between both subject groups Reference

Reduction of unexplained between subject variability (BSV) Volume of central compartment (V1) Reduction of unexplained BSV Marker: Median of 10 drugs, Box: inter-quartile range, Whisker: Min-Max Volume of peripheral compartment (V2)  None of the comparisons were statistically significant. Reference

Conclusions Allometric scaling by LBM: explained the difference in average CL and Vd between adult CF-patients and healthy volunteers reduced the unexplained BSV in renal clearance by 25% relative to linear scaling by WT allows one to –predict individual renal clearance more precisely –achieve target concentrations more precisely in adult CF-patients

Acknowledgement My warmest thank you to: All Clinical Study Teams All people in the bio-analytical lab Ms. Cornelia Landersdorfer Dr. Nick H. G. Holford Dr. George L. Drusano

Thank you very much for your attention.

Reduction of unexplained between subject variability (BSV) Reduction of unexplained BSV Marker: Median of 10 drugs, Box: inter-quartile range, Whisker: Min-Max 1.25 Ratio of averages: CL R (CF) / CL R (H) Median of 10 drugs 1.14 Reference Renal clearance

Renal clearance (CLr) CLr(CF) / CLr(H) CLnr(CF) / CLnr(H) Non-renal clearance (CLnr) Average ratios after size adjustment Marker: Median of 10 drugs, Box: inter-quartile range, Whisker: Min-Max